Acromegaly Completed Phase 4 Trials for Octreotide (DB00104)

Also known as: Acromegalic / Acromegaly (disorder)

Indication	Status	Phase
DBCOND0000951 (Acromegaly)	Completed	4

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01424241	Effects of Sandostatin LAR® in Acromegaly	Treatment	Octreotide (DB00104)
NCT01618513	Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target	Treatment	Octreotide (DB00104)
NCT01278342	Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients	Treatment	Cabergoline (DB00248) Octreotide (DB00104) Pegvisomant (DB00082)
NCT00595140	Acute Application of Pegvisomant and Octreotide in Acromegaly	Treatment	Cabergoline (DB00248) Dopamine (DB00988) Octreotide (DB00104) Pegvisomant (DB00082) Somatostatin (DB09099)
NCT00552071	Ultrasound Guided Octreotide LAR Injection in Acromegaly	Treatment	Octreotide (DB00104)
NCT00521300	Preoperative Octreotide Treatment of Acromegaly	Treatment	Octreotide (DB00104)
NCT00461149	Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly	Treatment	Octreotide (DB00104)
NCT00376064	Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly	Treatment	Cabergoline (DB00248) Octreotide (DB00104) Pegvisomant (DB00082)
NCT00171886	Octreotide Efficacy and Safety in First-line Acromegalic Patients	Treatment	Octreotide (DB00104)
NCT00145405	Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction	Treatment	Lanreotide (DB06791) Octreotide (DB00104)
NCT00068029	Pegvisomant And Sandostatin LAR Combination Study	Treatment	Octreotide (DB00104) Pegvisomant (DB00082)
NCT00068042	A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly	Treatment	Octreotide (DB00104) Pegvisomant (DB00082)